CD274 and neoplasm: Expression of programmed death ligand 1 (PD-L1) on the surface of T cells [4], the microsatellite instability (MSI) status [5] or DNA mismatch repair deficiency (dMMR) [6] and total tumor mutational burden (TMB) [7, 8] are the main predictive markers for the response to immunotherapy.